Tags

Type your tag names separated by a space and hit enter

Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up.
BMC Pulm Med. 2010 Apr 27; 10:23.BP

Abstract

BACKGROUND

8-Isoprostane (8-IP) is a marker of lipid peroxidation. Elevated concentrations have been reported in BAL fluid and exhaled breath condensate (EBC) in sarcoidosis (S). To validate the prognostic value of this marker we tested whether: 1. high initial EBC 8-IP predispose to more severe disease; 2. low initial concentrations increase a chance of early remission; 3. remissions are connected with the decrease of EBC 8-IP.

METHODS

40 patients (S) have been examined initially (V1) and after 8.5 +/- 0.5 months (V2). EBC 8-IP concentrations were measured by ELISA. Chest X-ray, lung function test, serum ACE and Ca2+ concentrations, 24 hrs Ca2+loss, abdominal ultrasonography, symptoms evaluation were performed.

RESULTS

We confirmed higher concentrations of 8-IP in EBC of patients with sarcoidosis (p = 0.001). Relative risk (RR) of persistence of disease at V2 when initial 8-IP was above 20 pg/mL was 1.04, and the frequency distributions estimated by chi2 test were not significantly different. A chance (RR) of early complete remission when V1 8-IP was below DL, was 3.33 (p = 0.04 by chi2 test). A significant decrease of 8-IP at V2 was observed only in patients who received treatment (p = 0.03), but not in those with spontaneous remission.

CONCLUSIONS

We come to the conclusion, that low initial 8-IP may be a positive prognostic factor. A decrease of 8-IP in treated patients reflects a non-specific effect of treatment and is not related to mere regression of disease.

Authors+Show Affiliations

Department of Pneumology and Allergy, Medical University of Lodz, Poland. piotrow@toya.net.plNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20420721

Citation

Piotrowski, Wojciech J., et al. "Exhaled 8-isoprostane as a Prognostic Marker in Sarcoidosis. a Short Term Follow-up." BMC Pulmonary Medicine, vol. 10, 2010, p. 23.
Piotrowski WJ, Kurmanowska Z, Antczak A, et al. Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up. BMC Pulm Med. 2010;10:23.
Piotrowski, W. J., Kurmanowska, Z., Antczak, A., Marczak, J., & Górski, P. (2010). Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up. BMC Pulmonary Medicine, 10, 23. https://doi.org/10.1186/1471-2466-10-23
Piotrowski WJ, et al. Exhaled 8-isoprostane as a Prognostic Marker in Sarcoidosis. a Short Term Follow-up. BMC Pulm Med. 2010 Apr 27;10:23. PubMed PMID: 20420721.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up. AU - Piotrowski,Wojciech J, AU - Kurmanowska,Zofia, AU - Antczak,Adam, AU - Marczak,Jerzy, AU - Górski,Paweł, Y1 - 2010/04/27/ PY - 2009/10/14/received PY - 2010/04/27/accepted PY - 2010/4/28/entrez PY - 2010/4/28/pubmed PY - 2010/9/18/medline SP - 23 EP - 23 JF - BMC pulmonary medicine JO - BMC Pulm Med VL - 10 N2 - BACKGROUND: 8-Isoprostane (8-IP) is a marker of lipid peroxidation. Elevated concentrations have been reported in BAL fluid and exhaled breath condensate (EBC) in sarcoidosis (S). To validate the prognostic value of this marker we tested whether: 1. high initial EBC 8-IP predispose to more severe disease; 2. low initial concentrations increase a chance of early remission; 3. remissions are connected with the decrease of EBC 8-IP. METHODS: 40 patients (S) have been examined initially (V1) and after 8.5 +/- 0.5 months (V2). EBC 8-IP concentrations were measured by ELISA. Chest X-ray, lung function test, serum ACE and Ca2+ concentrations, 24 hrs Ca2+loss, abdominal ultrasonography, symptoms evaluation were performed. RESULTS: We confirmed higher concentrations of 8-IP in EBC of patients with sarcoidosis (p = 0.001). Relative risk (RR) of persistence of disease at V2 when initial 8-IP was above 20 pg/mL was 1.04, and the frequency distributions estimated by chi2 test were not significantly different. A chance (RR) of early complete remission when V1 8-IP was below DL, was 3.33 (p = 0.04 by chi2 test). A significant decrease of 8-IP at V2 was observed only in patients who received treatment (p = 0.03), but not in those with spontaneous remission. CONCLUSIONS: We come to the conclusion, that low initial 8-IP may be a positive prognostic factor. A decrease of 8-IP in treated patients reflects a non-specific effect of treatment and is not related to mere regression of disease. SN - 1471-2466 UR - https://www.unboundmedicine.com/medline/citation/20420721/Exhaled_8_isoprostane_as_a_prognostic_marker_in_sarcoidosis__A_short_term_follow_up_ L2 - https://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-10-23 DB - PRIME DP - Unbound Medicine ER -